Non-invasive assessment of liver fibrosis in chronic liver diseases: Implementation in clinical practice and decisional algorithms

Figure 1 The SAFE-biopsy algorithm for significant fibrosis (≥ F2 by METAVIR). The figure reports the cut-offs used for APRI and Fibrotest in the decisional tree.

Figure 2 The SAFE-biopsy algorithm for cirrhosis (F4 by METAVIR). The figure reports the cut-offs used for APRI and Fibrotest in the decisional tree.

Figure 3 Diagnostic algorithms for implementation of non-invasive methods for liver fibrosis in clinical practice based on the local availability of the most validated methods.

Figure 4 Perspectives for the use of non-invasive markers for long term monitoring of chronic liver diseases.